Medimmune Limited

Nazzareno Dimasi

Philip Wilson Howard

Herren Wu

Changshou Gao

Ryan Fleming

Partha S Chowdhury

Binyam Bezabeh

Ralph Raymond Minter

Melissa Marie Damschroder

Charles K Stover

Bret Sellman

Godfrey Rainey

Reena Varkey

Sandrine Guillard

Ping Tsui

Ching Ching Leow

Cuihua Gao

Steven Rust

Antonio Digiandomenico

Mladen Tomich

Paul Warrener

Mario A Cepeda

Adrian Schwartz Mittelman

Karen Coffman

Vignesh Venkatraman

Li Peng

Dorin Toader

John H Li

Luke Masterson

Andy Q Yuan

Arnaud Charles Tiberghien

Srinath Kasturirangan

Yariv Mazor

Vaheh Oganesyan

Steven Roy Coats

Thais Cailleau

Lakshmaiah Gingipalli

Fengjiang Wang

Ronald James Christie

Pamela Thompson

Balakumar Vijayakrishnan

Jason White

Rust Steven

Melissa Damschroder

Partha Chowdhury

Andy Qingan Yuan

Ralph Minter

Charles Stover

This disclosure relates to combination therapies comprising anti-Psl and PcrV binding molecules and related compositions, for use in prevention and treatment ofinfection.

Combination therapies using anti-pseudomonas PSL and PCRV binding molecules

A conjugate of formula (I) wherein Ab is a modified antibody having at least one free conjugation site on each heavy chain. 

Pyrrolobenzodiazepine conjugates

The present invention relates to antibodies having activity against a vascular endothelial growth factor (VEGF), and methods of making and using such antibodies.

Nucleic acids encoding anti-VEGF-A antibodies and uses thereof

The present invention relates to bispecific antibodies having activity against a vascular endothelial growth factor (VEGF) and an angiopoietin (ANG), and methods of making and using such bispecific antibodies.

Nucleic acids encoding bispecific anti-VEGF and anti-ANG2 antibodies and uses thereof

The present disclosure relates to a process for preparing antibodies with a defined glycosylation pattern, in particular antibodies with a glycan terminating in an N-acetylglucosamine. The antibodies of the disclosure are suitable for use in a process to conjugate a payload thereto. The disclosure also extends to molecules obtained and obtainable from the process disclosed herein, novel molecules and intermediates, compositions comprising said molecules and uses of the molecules and compositions, particularly in treatment, for example in the treatment of cancer.

Methods for preparing antibodies with a defined glycosylation pattern

This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind toPcrV as well as vectors and host cells comprising the same.

Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv

Anti-VEGF-A antibodies and uses thereof

Anti-VEGF-A and anti-ANG2 antibodies and uses thereof

The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.

Bispecific HER2 antibodies

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.

Multispecific and multivalent binding proteins and uses thereof

The technology relates in part to engineered antibodies. In particular, multispecific engineered antibodies. Such antibodies can be utilized for diagnostic and therapeutic applications in some aspects.

Modified polypeptides for bispecific antibody scaffolds

Growing community of inventors

Gaithersburg, MD, United States of America

Nazzareno Dimasi